When Will Retatrutide Be Available in the UK? 2025 Update
Retatrutide is one of the most anticipated weight loss drugs in pharmaceutical history — but it is not yet approved for prescription use in the UK or anywhere else. Here’s the current status of clinical trials, the expected MHRA approval timeline and what it means for UK buyers today.
Where Is Retatrutide in Clinical Development?
Phase 2 — Completed (2023)
The Phase 2 trial was completed and published in the New England Journal of Medicine in June 2023. Results were highly significant: 24.2% average body weight reduction at the 24mg dose over 48 weeks — making retatrutide the most effective GLP-1 class peptide ever tested in a clinical trial.
Phase 3 — Currently Ongoing
Eli Lilly launched the Phase 3 TRIUMPH programme for retatrutide in 2023-2024. Multiple Phase 3 trials are running, including:
- TRIUMPH-1: Long-term weight management efficacy and safety in adults with obesity
- TRIUMPH-CVD: Cardiovascular outcomes trial (required by regulatory agencies before approval)
- TRIUMPH-T2D: Type 2 diabetes efficacy trial
Current trial status: View all retatrutide trials on ClinicalTrials.gov →
Expected MHRA Approval Timeline
Regulatory approval requires completing Phase 3 trials, compiling the full clinical data package and submitting a Marketing Authorisation Application (MAA) to the MHRA (UK) and NDA to the FDA (US). Based on typical timelines:
- Phase 3 completion (estimated): 2025–2026
- Regulatory submission: 2026
- MHRA/FDA review period: 12–18 months
- Earliest possible UK approval: Late 2026 to 2027
- NHS availability after approval: Additional 12–24 months (NICE assessment required)
Realistic expectation: Retatrutide will not be available on UK NHS prescription until 2027–2029 at the earliest. Private prescription may be available sooner after MHRA approval.
What Will the Brand-Name Price Be?
Based on pricing precedents from Ozempic® and Mounjaro® after approval, brand-name retatrutide will almost certainly be priced at £800–£1,500/month or more in the UK. Mounjaro® (tirzepatide) launched in the UK at £1,050–£1,400/month. Retatrutide, being a more complex and effective molecule, will likely be priced at a premium above Mounjaro®.
How to Get Retatrutide in the UK Right Now
While retatrutide awaits MHRA approval, it is available in the UK as a compounded research peptide. At UK Peptides Store, we currently stock:
- Synedica Retatrutide 40mg — £299/month
- Alluvi Retatrutide 40mg — £299/month
- Alluvi Retatrutide 20mg — £249/month
- VLS Retatrutide 40mg — £265/month
All independently COA verified, physician-supervised, dispatched from Manchester within 48 hours. The compounded price will also remain significantly below the brand-name price even after approval — as we have seen with semaglutide where compounded versions remain at £199/month vs Ozempic®’s £900+/month.
Questions? WhatsApp our team →